GPC Biotech's Satraplatin Shown To Significantly Reduce Risk Of Disease Progression In Advanced Hormone-Refractory Prostate Cancer Patients
BOULDER, Colo., MARTINSRIED/MUNICH, Germany, WALTHAM, Mass., and PRINCETON, N.J., Feb. 23 -- Pharmion Corporation and GPC Biotech AG today announced that final progression-free survival (PFS) results for the double-blind, randomized satraplatin Phase 3 registrational trial, the SPARC trial (Satraplatin and Prednisone Against Refractory Cancer) are being presented today at the ASCO Prostate Cancer Symposium in Orlando, Florida. The trial is evaluating satraplatin plus prednisone versus placebo plus prednisone in 950 patients with hormone-refractory prostate cancer (HRPC) who have failed prior chemotherapy. All analyses of PFS being presented were conducted on an intent-to-treat basis.
The study data show that satraplatin significantly reduces the risk of disease progression in these patients using the protocol-specified log-rank test. The hazard ratio of 0.6 (95% CI: 0.5-0.7, p